São Paolo-based health tech startup Sami announced it raised $18 million in Series B funding led by Redpoint eventures and Mundi Ventures.
Alumni Ventures, Digital Horizon, Tau Ventures and Endeavor Catalyst also participated in the round alongside current investors Valor Capital, monashees, Kevin Efrusy of Accel, Ricardo Marino of Itaú, Mancora Ventures, Mauro Figueiredo and Brad Otto, a former executive of UnitedHealth Group.
The company offers corporate health insurance plans. With its recent capital raise, Sami will expand its offerings to be available through healthcare brokers, in addition to its online format and direct sales approach.
Sami will also use the funds to scale its platform and implement new technology-based tools.
“In the last two years, we have built a base of products and operations that will allow us to rapidly scale. To this end, we have to be where the customer wants to buy, be it on [the] internet, on mobile devices, or from a broker,” Guilherme Berardo, CEO of Sami, said in a statement.
The Brazilian company announced it had scored $15.5 million in funding in 2020, the largest Series A round on record for a Latin American health startup at the time.
Indiana-based RxLightning, a digital distribution platform for specialty medication, scored $17.5 million in Series A funding, bringing its total raise to $20.5 million.
LRVHealth led the round, with participation from McKesson Ventures. Existing investors Novartis (dRX Capital), Hearst Ventures, Onco360 and HealthX Ventures also provided funding.
Mark Bakken of HealthX Ventures, Josh Flum of LRV Health and Carrie Williams of McKesson Ventures will join RxLightning’s board of directors.
The company offers an enrollment platform to streamline the specialty medication onboarding process for providers.
The funds will be used to support the company’s growth.
Canadian fertility and reproductive health company Twig closed an $8 million Series A funding round led by Rhino Ventures.
Twig’s offerings include in-vitro fertilization, intrauterine insemination, egg freezing, reproductive genetic counseling, LGBTQ family building, fertility checks, reproductive urology, and mental health and wellness support. The company utilizes demographic data to optimize patient treatment.
The company will use the funds to speed up growth, expand its footprint and develop its technology platform.
“Canada has the lowest per capita use of fertility treatments in the G7, and we believe that is directly related to accessibility and cost,” Jay Rhind, partner at Rhino Ventures, said in a statement. “Twig Fertility’s vision for personalized care and their dedication to improving patient outcomes addresses a critical need in the Canadian market.”